Novartis buys Fougera for $1.5 billion cash to boost Sandoz dermatology business
This article was originally published in Scrip
Executive Summary
Novartis will pay $1.5 billion in cash to acquire the private, specialized US firm Fougera Pharmaceuticals and make its generics division Sandoz the number one generic dermatology medicines company in the world with an estimated $620 million in annual global sales.